MarketPulse

cardiovascular

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Immutrin Bolsters Leadership With Cardiovascular Expert as CMO, Launches US Operations

Biotech firm Immutrin appoints Dr. Robert Blaustein as Chief Medical Officer and establishes US subsidiary to advance amyloidosis antibody therapy toward clinical trials.
MRKEWTXclinical developmentcardiovascular
BenzingaBenzinga··Na

Athyrium Backs Esperion's $50M Japan Deal to Fund Corstasis Acquisition

Athyrium invests $50M in Esperion via Japan royalty financing to fund Corstasis acquisition, bringing first FDA-approved intranasal loop diuretic to portfolio.
ESPRM&AJapan market
BenzingaBenzinga··Na

Esperion Closes Corstasis Acquisition, Adds First Nasal Spray Loop Diuretic to CV Portfolio

Esperion closes Corstasis acquisition, gaining FDA-approved Enbumyst nasal spray loop diuretic for heart failure treatment, leveraging existing cardiovascular commercial infrastructure.
ESPRacquisitionFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Esperion Closes Corstasis Deal, Adding First Nasal Loop Diuretic to Heart Drug Arsenal

Esperion completes acquisition of Corstasis, adding Enbumyst, first FDA-approved nasal spray loop diuretic, to expand its cardiovascular product portfolio.
ESPRacquisitionFDA approval
BenzingaBenzinga··Nabaparna Bhattacharya

Esperion Acquires Enbumyst Maker Corstasis for $75M in Cash-Plus-Milestone Deal

Esperion acquires Corstasis for $75M upfront plus $180M in milestones, gaining FDA-approved nasal spray diuretic Enbumyst for heart failure treatment.
ESPRacquisitionFDA-approved